Trials / Completed
CompletedNCT01991509
Safety and Bioavailability of IV and SC LBR-101
A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study Assessing the Safety, Tolerability and Pharmacokinetics of Two Different Doses of LBR-101 Given Intravenously and Subcutaneously
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability and blood levels of LBR-101 when administered intravenously or subcutaneously to healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LBR-101 IV | LBR-101 Administered Intravenously |
| BIOLOGICAL | LBR-101 SC | LBR-101 Administered Subcutaneously |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2014-12-01
- Completion
- 2015-01-01
- First posted
- 2013-11-25
- Last updated
- 2015-03-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01991509. Inclusion in this directory is not an endorsement.